The Role of Neutrophils in the Age-driven Decline in Anti-pneumococcal Vaccine Responses
ConditionAging
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age21+
SponsorState University of New York at Buffalo
About this trial
This study focuses on the role of neutrophils in shaping the adaptive immune response to the anti-pneumococcal vaccine Prevnar-13 in young and elderly adults.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Both sexes
Have not been vaccinated with any licensed or experimental pneumococcal vaccine
Ages 21-40; and ≥65. Individuals >60 years old will also be recruited in case we find no unvaccinated people ≥65 years old
Free of acute infections within the last 2 weeks
Disqualifiers
Previous vaccination with any licensed or experimental pneumococcal vaccine
Known hypersensitivity to vaccination and vaccine components
Immune deficiency
Use of immune-modulating or suppressive drugs
Trial design
Design model
Single group
Treatments tested in this trial
vaccine
Other interventionVaccination against 20 serotypes of S. pneumoniae
Treatment groups
60 Participants
are divided into 1 treatment groupGroup A: Vaccination with Prevnar.Experimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Pneumococcal Opsonophagocytic Killing Activity (OPH) by neutrophils from young versus old donors at 1 week and 1 month after vaccination
OPH will be determined by measuring the percentage of S. pneumoniae bacteria killed in vitro by neutrophils from donors
Time frame
1 monthSecondary outcomes
1
Surface phenotype of neutrophils from young versus old donors at 1 week and 1 month after vaccination
Phenotype will be determined by measuring the expression of surface receptors on neutrophils ex vivo by flowcytometry from donors
Time frame
1 monthSponsors and contacts
Click on the lead sponsor to view all of their trials.
State University of New York at Buffalo
Lead sponsor
National Institute on Aging (NIA)
Collaborator
Source ClinicalTrials.gov